Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Isaac G. Sakala"'
Autor:
Deepender Kaushik, Simran Dhingra, Madhuri T. Patil, Sakshi Piplani, Varun Khanna, Yoshikazu Honda-Okubo, Lei Li, Johnson Fung, Isaac G. Sakala, Deepak B. Salunke, Nikolai Petrovsky
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 8, Pp 1989-1996 (2020)
Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinol
Externí odkaz:
https://doaj.org/article/2cd2603c6eb1498d8e7b8399fcbe1589
Autor:
Arshpreet Kaur, Sakshi Piplani, Deepender Kaushik, Johnson Fung, Isaac G. Sakala, Yoshikazu Honda-Okubo, Surinder K. Mehta, Nikolai Petrovsky, Deepak B. Salunke
Publikováno v:
RSC Medicinal Chemistry. 13:622-637
Lipopeptides including diacylated Pam2CSK4as well as triacylated Pam3CSK4act as ligands of toll-like receptor (TLR)-2, a promising target for the development of vaccine adjuvants.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49c3d4f65c5d9fba74ea5f273f76894a
https://doi.org/10.1039/d1md00372k
https://doi.org/10.1039/d1md00372k
Autor:
Yoshikazu Honda-Okubo, Lei Li, Nikolai Petrovsky, Jeremy Baldwin, Sakshi Piplani, Isaac G. Sakala
Publikováno v:
Bioanalysis
Vaccines are key in charting a path out of the COVID-19 pandemic. However, development of new vaccines is highly dependent on availability of analytical methods for their design and evaluation. This paper highlights the challenges presented in having
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c26dcc86128aa502d3e19b710363f08
https://doi.org/10.4155/bio-2021-0096
https://doi.org/10.4155/bio-2021-0096
Autor:
Lei Li, Deepak B. Salunke, Johnson Fung, Varun Khanna, Deepender Kaushik, Yoshikazu Honda-Okubo, Madhuri T. Patil, Isaac G. Sakala, Nikolai Petrovsky, Sakshi Piplani, Simran Dhingra
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb14de778597f37bb359cedd13298681
https://doi.org/10.1080/21645515.2019.1710409
https://doi.org/10.1080/21645515.2019.1710409
Autor:
Isaac G Sakala, Geeta Chaudhri, Anthony A Scalzo, Preethi Eldi, Timothy P Newsome, Robert M Buller, Gunasegaran Karupiah
Publikováno v:
PLoS Pathogens, Vol 11, Iss 12, p e1005342 (2015)
Orthopoxviruses (OPV), including variola, vaccinia, monkeypox, cowpox and ectromelia viruses cause acute infections in their hosts. With the exception of variola virus (VARV), the etiological agent of smallpox, other OPV have been reported to persist
Externí odkaz:
https://doaj.org/article/cea6de08645b4ef199a3c893657675ec
Autor:
Arshpreet, Kaur, Sakshi, Piplani, Deepender, Kaushik, Johnson, Fung, Isaac G, Sakala, Yoshikazu, Honda-Okubo, Surinder K, Mehta, Nikolai, Petrovsky, Deepak B, Salunke
Publikováno v:
RSC Med Chem
Lipopeptides including diacylated Pam(2)CSK(4) as well as triacylated Pam(3)CSK(4) act as ligands of toll-like receptor (TLR)-2, a promising target for the development of vaccine adjuvants. The highly investigated Pam(2)CSK(4) and Pam(3)CSK(4), despi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c479870864a6721c22174365b7981de1
https://pubmed.ncbi.nlm.nih.gov/35694694
https://pubmed.ncbi.nlm.nih.gov/35694694
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0118685 (2015)
Ectromelia virus (ECTV) causes mousepox in mice, a disease very similar to smallpox in humans. ECTV and variola virus (VARV), the agent of smallpox, are closely related orthopoxviruses. Mousepox is an excellent small animal model to study the genetic
Externí odkaz:
https://doaj.org/article/8506ae10a8074e91b7ecf48dde8d96cb
Autor:
Arshpreet Kaur, Rohini Kanwar, Deepender Kaushik, Isaac G. Sakala, Yoshikazu Honda-Okubo, Nikolai Petrovsky, Deepak B. Salunke, Surinder K. Mehta
Publikováno v:
International journal of pharmaceutics. 613
Toll-like receptor (TLR) agonists are promising adjuvants and the combination of TLR agonists enhance immune responses by providing synergistic immune activity via triggering different signalling pathways. However, systematic cytotoxicity due to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9c2701f4846e144a23b1cbd215f57a
https://pubmed.ncbi.nlm.nih.gov/34915144
https://pubmed.ncbi.nlm.nih.gov/34915144
Publikováno v:
Expert Review of Clinical Immunology
Introduction: Neonates are less responsive to vaccines than adults, making it harder to protect newborns against infection. Neonatal differences in antigen-presenting cell, B and T cell function, all likely contribute. A key question is whether novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed7bad7928c87f8dddc28d1d5974312
http://europepmc.org/articles/PMC6678067
http://europepmc.org/articles/PMC6678067
Publikováno v:
Vaccine. 39(36)
Background Despite newborns being at increased risk of serious influenza infection, influenza vaccines are currently not recommended for use in infants under 6 months of age. We therefore sought to evaluate the protective efficacy in mice of an M2-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a95aacfb678ff050f91547621528bf1
https://pubmed.ncbi.nlm.nih.gov/34362601
https://pubmed.ncbi.nlm.nih.gov/34362601